[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoadjuvant-therapy-in-rectal-cancer-radiotherapy-folfox\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoadjuvant-therapy-in-rectal-cancer-radiotherapy-folfox":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100468372","phase-2-neoadjuvant-therapy-vs-standard-therapy-in-locally-advanced-rectal-cancer-100468372",false,"NCT05378919","Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer","Evaluation and Comparison of the Efficacy of a New Standard Pre-operative Chemotherapy for Stage II and III Colorectal Cancer According to the FOLFOX4 Regimen With Routine Chemoradiation Therapy","RECTUM2015","Inclusion Criteria:\n\n* diagnosed with rectal adenocarcinoma;\n* radiologically measurable tumor size;\n* general condition (ECOG 0-2 points);\n* stage II or III rectal tumor clinically (pelvic MRI and endorectal ultrasound),\n* in the absence of long-term spread of the disease (confirmed by radiological examinations (computed tomography of the thorax and abdomen));\n* during preoperative proctoscopy, the tumor is detected 0 -15 cm from the anus;\n* Blood tests 28 days before the start of treatment:\n\nand general blood count: neutrophils greater than 1.5x10 9 \u002F l, platelets greater than 100 x 10 9 \u002F l, Hemoglobin greater than 80 g \u002F l, liver enzymes (Aspartate aminotransferase (AST\u002FGOT), alanine aminotransferase (ALT\u002FGPT) not more than 3 times upper limit), and renal function (creatinine up to 1.5 times the upper limit of normal) is normal; women of childbearing potential - negative pregnancy test;\n\n• A signed informed consent form.\n\nExclusion Criteria:\n\n* patients with signs of intestinal obstruction at the start of treatment;\n* previous lower abdominal radiation therapy;\n* other tumors over a five-year period;\n* pregnant or breastfeeding women;\n* men and women of childbearing potential who do not agree to use adequate contraception;\n* Patient co-morbidities that would make the patient unsuitable for this study or significantly interfere with the assessment of safety and toxicity.","ALL","18 Years",{"count":20,"type":21},250,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Phase II, Multicenter, Open-label, Randomized Study evaluating neoadjuvant chemotherapy (FOLFOX4) in patients with stage II and III colorectal cancer with standard chemoradiation Defined by Magnetic Resonance Imaging",[27],"Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX","RECRUITING","2022-05-12",{"date":31,"type":32},"2022-05-18","ACTUAL",{"date":34,"type":32},"2015-06-01",{"date":36,"type":21},"2027-06-01",{"name":38,"class":39},"Lithuanian University of Health Sciences","OTHER"]